Capricor Investor News: If You Have Suffered Losses in Capricor Therapeutics Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm announced an investigation into Capricor Therapeutics Inc. following FDA staff concerns about effectiveness data for the company's experimental cell therapy (deramiocel) for a heart condition related to Duchenne muscular dystrophy. The disclosure caused Capricor's stock to plunge 64-65% on July 27, 2026. The firm is preparing a class action lawsuit to recover investor losses.

08/02/2026, 12:10 PM • GlobeNewswire

CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC

The FDA announced that Capricor Therapeutics' stem cell treatment for Duchenne muscular dystrophy did not meet the objectives of its Phase 3 trial, contradicting the company's claims from the previous year. Following this disclosure, Capricor's stock price declined significantly.

07/30/2026, 1:52 PM • GlobeNewswire

Lowey Dannenberg, P.C. is Investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) for Potential Violations of the Federal Securities Laws

Law firm Lowey Dannenberg is investigating Capricor Therapeutics for potential federal securities violations following disclosure that FDA briefing materials relied on an outdated statistical analysis plan for its Deramiocel therapy BLA. The stock fell 64% after the disclosure, and an FDA Advisory Committee subsequently voted against the drug's effectiveness for cardiomyopathy in DMD patients.

07/30/2026, 12:38 PM • GlobeNewswire

CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation

The FDA released briefing materials on July 27, 2026, raising concerns about Capricor Therapeutics' deramiocel cell therapy for treating cardiomyopathy associated with Duchenne muscular dystrophy. The FDA's advisory panel voted 9-3 against the therapy, citing insufficient evidence of effectiveness and concerns that the company changed how it measured trial results. Following the announcement, Capricor's stock price plummeted approximately 67% on July 29, 2026, and fell another 50% in premarket trading on July 30, 2026.

07/30/2026, 8:53 AM • GlobeNewswire

CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash

Hagens Berman has opened an investigation into Capricor Therapeutics following a 64% stock collapse on July 27, 2026. The FDA's briefing document revealed that the company's lead drug candidate Deramiocel failed to meet pre-specified primary and secondary efficacy endpoints in the Phase 3 HOPE-3 trial, contradicting Capricor's December 2025 announcement of 'positive' results. The investigation focuses on whether Capricor misled investors about trial efficacy and undisclosed changes to the statistical analysis plan.

07/29/2026, 10:51 PM • GlobeNewswire

Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

Johnson Fistel is investigating Capricor Therapeutics for potential securities law violations following FDA staff concerns about the company's deramiocel heart therapy trial data. The FDA raised questions about how Capricor changed its measurement methodology post-trial and whether the trial population actually had the targeted heart condition. The stock declined approximately 70% on July 27, 2026, following the Reuters report of these FDA concerns.

07/27/2026, 1:58 PM • GlobeNewswire

BREAKING: Capricor Therapeutics Investigated for Securities Fraud by Block & Leviton; Investors Should Contact the Firm to Learn More

Block & Leviton is investigating Capricor Therapeutics for potential securities law violations related to misrepresentations about its deramiocel cell therapy regulatory pathway. The FDA concluded the therapy lacked substantial evidence of effectiveness, contradicting the company's prior statements about its Biologics License Application being on track. Capricor shares fell over 60% following the FDA's negative assessment.

07/27/2026, 12:44 PM • GlobeNewswire

This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy?

Capricor Therapeutics' EVP and General Counsel Karen Krasney sold 24,100 shares for ~$732,000 in June 2026 through a pre-planned 10b5-1 trading arrangement, which is routine stock-based compensation and not indicative of insider concerns. The stock has declined 30% year-to-date after a 202% surge in 2025. An FDA decision on Deramiocel approval is expected by August 22, 2026, which could serve as a significant catalyst for the clinical-stage biotech company.

07/25/2026, 7:11 AM • The Motley Fool

Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.

05/26/2026, 1:00 PM • GlobeNewswire

Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story

Karen Krasney, EVP and General Counsel of Capricor Therapeutics, exercised and sold 25,000 stock options for approximately $793,000 on May 1, 2026, reducing her direct equity position by 45%. The sale was executed under a pre-scheduled 10b5-1 trading plan established in December 2025, indicating a diversification move rather than a loss of confidence. Krasney retains 30,547 common shares and 56,261 unexercised options, maintaining material exposure to the company.

05/10/2026, 7:01 AM • The Motley Fool

Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say

Capricor Therapeutics announced positive Phase 3 HOPE-3 trial results for its cell therapy candidate deramiocel, causing its stock to surge dramatically. Martin Shkreli, who had previously predicted the trial's failure, criticized the data and claimed the company changed its primary endpoint.

12/03/2025, 2:21 PM • Benzinga

Why Capricor Therapeutics Stock Is Surging Today

Capricor Therapeutics met with the FDA to discuss regulatory approval for Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy. The FDA provided clarity on the approval process and showed flexibility in reviewing trial data, causing the stock to surge.

09/25/2025, 11:16 AM • Benzinga

Shareholders of Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights – CAPR

Capricor Therapeutics received a Complete Response Letter from the FDA denying its Biologics License Application for deramiocel, causing a significant stock price drop and triggering a potential securities class action lawsuit.

09/15/2025, 3:58 PM • GlobeNewswire

CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against Capricor Therapeutics alleging false and misleading statements about the safety and efficacy of its Phase 2 HOPE-2 trial for deramiocel, with potential regulatory approval challenges.

09/14/2025, 4:00 PM • GlobeNewswire

CAPR IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in Securities Class Action – CAPR

Rosen Law Firm is pursuing a securities class action lawsuit against Therapeutics for allegedly providing misleading statements about its cell therapy drug deramiocel and its Phase 2 trial data, potentially causing investor damages.

09/14/2025, 9:44 AM • GlobeNewswire